PYC Therapeutics Launches Major Capital Raising to Advance Four Clinical Programs
PYC Therapeutics Limited (ASX: PYC) has announced a significant equity fundraising of up to AU$653 million to progress four high-potential drug candidates through key human efficacy milestones. The capital raise comprises a AU$128 million placement to leading US-based specialist life sciences investors, alongside a AU$525 million accelerated non-renounceable entitlement offer to eligible shareholders. New shares will be issued at AU$1.50 per share, representing a modest discount to the prior trading price and theoretical ex-rights price. PYC has already secured binding commitments for approximately AU$560 million, providing strong execution certainty. Proceeds are expected to fully fund the company through to calendar year 2030 and support advancement of programs targeting polycystic kidney disease, Phelan-McDermid syndrome, retinitis pigmentosa type 11, and autosomal dominant optic atrophy. The raise materially strengthens PYC’s balance sheet and accelerates clinical development across its pipeline.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
PYC Therapeutics Launches Major Capital Raising to Advance Four Clinical Programs
PYC Therapeutics Limited (ASX: PYC) has announced a significant equity fundraising of up to AU$653 million to progress four high-potential drug candidates through key human efficacy milestones. The capital raise comprises a AU$128 million placement to leading US-based specialist life sciences investors, alongside a AU$525 million accelerated non-renounceable entitlement offer to eligible shareholders. New shares will be issued at AU$1.50 per share, representing a modest discount to the prior trading price and theoretical ex-rights price. PYC has already secured binding commitments for approximately AU$560 million, providing strong execution certainty. Proceeds are expected to fully fund the company through to calendar year 2030 and support advancement of programs targeting polycystic kidney disease, Phelan-McDermid syndrome, retinitis pigmentosa type 11, and autosomal dominant optic atrophy. The raise materially strengthens PYC’s balance sheet and accelerates clinical development across its pipeline.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au